May 29, 2020 - Page 11 of 17

NYSE Companies - May 29, 2020

Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine

Phase 3 data presented in oral presentation during the ASCO20 Virtual Scientific Program, with simultaneous publication in the New England […]

NASDAQ Companies - May 29, 2020

Mondelēz International Participates in JDE Peet’s IPO; Retains Significant Stake

Mondelēz International contributed to JDE Peet’s successful listing on Euronext AmsterdamCompany will retain two board seats at the global coffee […]

NASDAQ Companies - May 29, 2020

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

REDIRECT is a Registration-directed Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with […]

NASDAQ Companies - May 29, 2020

NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting

BELTSVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and […]

NASDAQ Companies - May 29, 2020

Charles & Colvard Appoints Don O’Connell as President and Chief Executive Officer

RESEARCH TRIANGLE PARK, N.C., May 29, 2020 (GLOBE NEWSWIRE) — Charles & Colvard, Ltd. (Nasdaq: CTHR), (the “Company”), the original […]

NASDAQ Companies - May 29, 2020

CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program

– First Presentation of Clinical Data for CX-2029, a Probody Drug Conjugate, Directed Against CD71: A Previously Undruggable Target –– Data […]

NASDAQ Companies - May 29, 2020

Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up36.4% Overall Response Rate (ORR) MaintainedSAN CARLOS, […]

NASDAQ Companies - May 29, 2020

Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting

HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense […]

NASDAQ Companies - May 29, 2020

Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics

– Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020– […]

NASDAQ Companies - May 29, 2020

BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

– Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared […]